506 related articles for article (PubMed ID: 24749737)
1. Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry.
Li Y; Hewitt D; Lentz YK; Ji JA; Zhang TY; Zhang K
Anal Chem; 2014 May; 86(10):5150-7. PubMed ID: 24749737
[TBL] [Abstract][Full Text] [Related]
2. On-line coupling of hydrophobic interaction column with reverse phase column -charged aerosol detector/mass spectrometer to characterize polysorbates in therapeutic protein formulations.
He Y; Brown P; Bailey Piatchek MR; Carroll JA; Jones MT
J Chromatogr A; 2019 Feb; 1586():72-81. PubMed ID: 30551943
[TBL] [Abstract][Full Text] [Related]
3. High throughput multidimensional liquid chromatography approach for online protein removal and characterization of polysorbates and poloxamer in monoclonal antibody formulations.
Zegota MM; Schuster G; De Pra M; Müllner T; Menzen T; Steiner F; Hawe A
J Chromatogr A; 2024 Apr; 1720():464777. PubMed ID: 38432108
[TBL] [Abstract][Full Text] [Related]
4. Impact of mono- and poly-ester fractions on polysorbate quantitation using mixed-mode HPLC-CAD/ELSD and the fluorescence micelle assay.
Lippold S; Koshari SHS; Kopf R; Schuller R; Buckel T; Zarraga IE; Koehn H
J Pharm Biomed Anal; 2017 Jan; 132():24-34. PubMed ID: 27693757
[TBL] [Abstract][Full Text] [Related]
5. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
[TBL] [Abstract][Full Text] [Related]
6. Mixed-mode and reversed-phase liquid chromatography-tandem mass spectrometry methodologies to study composition and base hydrolysis of polysorbate 20 and 80.
Hewitt D; Alvarez M; Robinson K; Ji J; Wang YJ; Kao YH; Zhang T
J Chromatogr A; 2011 Apr; 1218(15):2138-45. PubMed ID: 20950816
[TBL] [Abstract][Full Text] [Related]
7. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
Tomlinson A; Zarraga IE; Demeule B
Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
[TBL] [Abstract][Full Text] [Related]
9. Acidic and alkaline hydrolysis of polysorbates under aqueous conditions: Towards understanding polysorbate degradation in biopharmaceutical formulations.
Dwivedi M; Buske J; Haemmerling F; Blech M; Garidel P
Eur J Pharm Sci; 2020 Mar; 144():105211. PubMed ID: 31931121
[TBL] [Abstract][Full Text] [Related]
10. Impact of Stainless Steel Exposure on the Oxidation of Polysorbate 80 in Histidine Placebo and Active Monoclonal Antibody Formulation.
Gopalrathnam G; Sharma AN; Dodd SW; Huang L
PDA J Pharm Sci Technol; 2018; 72(2):163-175. PubMed ID: 29343621
[TBL] [Abstract][Full Text] [Related]
11. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
Tomlinson A; Demeule B; Lin B; Yadav S
Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
[TBL] [Abstract][Full Text] [Related]
12. Stability of the non-ionic surfactant polysorbate 80 investigated by HPLC-MS and charged aerosol detector.
Christiansen A; Backensfeld T; Kühn S; Weitschies W
Pharmazie; 2011 Sep; 66(9):666-71. PubMed ID: 22026121
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a selective marker-based quantification of polysorbate 20 in biopharmaceutical formulations using UPLC QDa detection.
Evers DH; Schultz-Fademrecht T; Garidel P; Buske J
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1157():122287. PubMed ID: 33069954
[TBL] [Abstract][Full Text] [Related]
14. Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations.
Labrenz SR
J Pharm Sci; 2014 Aug; 103(8):2268-77. PubMed ID: 24942482
[TBL] [Abstract][Full Text] [Related]
15. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
[TBL] [Abstract][Full Text] [Related]
16. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
[TBL] [Abstract][Full Text] [Related]
17. Investigation of excipients impact on polysorbate 80 degradation in biopharmaceutical formulation buffers.
Bai L; Zhang Y; Zhang C; Lu Y; Li Z; Huang G; Meng B
J Pharm Biomed Anal; 2023 Sep; 233():115496. PubMed ID: 37285658
[TBL] [Abstract][Full Text] [Related]
18. Effect of polysorbate 80 quality on photostability of a monoclonal antibody.
Singh SR; Zhang J; O'Dell C; Hsieh MC; Goldstein J; Liu J; Srivastava A
AAPS PharmSciTech; 2012 Jun; 13(2):422-30. PubMed ID: 22362139
[TBL] [Abstract][Full Text] [Related]
19. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038
[TBL] [Abstract][Full Text] [Related]
20. Surface activity of a monoclonal antibody.
Mahler HC; Senner F; Maeder K; Mueller R
J Pharm Sci; 2009 Dec; 98(12):4525-33. PubMed ID: 19655376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
